Blood test study for mastocytosis mutation detection
Part of Cancer, Immune system & allergy clinical trials.
This study looks for a specific genetic change (KIT-D816V mutation) in the blood of adults with mast cell disorders—conditions where immune cells called mast cells cause allergic-like reactions. Understanding this mutation may help doctors better diagnose and treat your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have symptoms like unexplained severe allergic reactions, flushing, stomach pain, diarrhea, hives, or a skin condition called urticaria pigmentosa
- You have not taken KIT inhibitor drugs (like imatinib or avapritinib) in the past 3 months
- You have not taken steroids, interferon, or immunosuppressive drugs in the past month
- You are able to have blood drawn and a bone marrow biopsy (a needle sample from your hip bone), and willing to return for check-ups every 6 months for 6 months
- You do not have other blood cancers or clotting problems that would prevent safe blood or bone marrow collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for a specific gene change (KIT D816V) in people with certain allergic reactions or related conditions. It aims to find those who might benefit from future treatments targeting this mutation.
This study looks at people with a slow-growing type of mast cell disease called indolent systemic mastocytosis. The goal is to better understand the condition and how to manage it, using your genetic information to guide future care.
This study looks at what causes mast cells to grow too much in people with mastocytosis. It may help researchers find better ways to diagnose or treat this condition. You can take part in person or by telehealth.
This trial collects blood and tissue samples to better understand allergies, asthma, and mast cell conditions. It aims to find markers that could improve diagnosis and treatment. Participation involves donating samples and sharing medical history.
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
This study looks at whether mast cells, a type of immune cell, play a role in autoinflammatory diseases. It compares blood samples from patients with these diseases, healthy people, and people with mastocytosis to find new clues for better treatments.
Hear when a new Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.